Abstract
The current national treatment scenario for relapsed / refractory multiple myeloma (RRMM) and the effectiveness of the different treatment alternatives in daily clinical practice outside clinical trials (CT) is unknown. In recent years, several treatment regimens have been approved representing effective treatment alternatives and a hope for a better-quality of life for patients, according to the results obtained in CT. It is necessary to evaluate the results of these treatments in daily clinical practice in order to elucidate the real impact of the incorporation of new treatments to the therapeutic arsenal already available and to know as objectively as possible the benefit they bring to the patients.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
